Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.3.909

Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study  

Zeng, Yin-Duo (Department of Medical Oncology, Cancer Center, Sun Yat-sen University)
Zhang, Li (Department of Medical Oncology, Cancer Center, Sun Yat-sen University)
Liao, Hai (Department of Medical Oncology, Cancer Center, Sun Yat-sen University)
Liang, Ying (Department of Medical Oncology, Cancer Center, Sun Yat-sen University)
Xu, Fei (Department of Medical Oncology, Cancer Center, Sun Yat-sen University)
Liu, Jun-Ling (Department of Medical Oncology, Cancer Center, Sun Yat-sen University)
Dinglin, Xiao-Xiao (Department of Medical Oncology, Cancer Center, Sun Yat-sen University)
Chen, Li-Kun (Department of Medical Oncology, Cancer Center, Sun Yat-sen University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.3, 2012 , pp. 909-914 More about this Journal
Abstract
Background: Gefitinib, a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), is used both as a single drug and concurrently with whole brain radiotherapy (WBRT) the standard treatment for brain metastases (BM), and is reported to be effective in a few small studies of patients with BM from non-small-cell lung cancer (NSCLC). However, no study has compared the two treatment modalities. This retrospective analysis was conducted to compare the efficacy of gefitinib alone with gefitinib plus concomitant WBRT in treatment of BM from NSCLC. Methods: We retrospectively reviewed 90 patients with BM from NSCLC who received gefitinib alone (250mg/day, gefitinib group) or with concomitant WBRT (40Gy/20f/4w, gefitinib-WBRT group) between September 2005 and September 2009 at Sun Yat-Sen University Cancer Center. Forty-five patients were in each group. Results: The objective response rate of BM was significantly higher in gefitinib-WBRT group (64.4%) compared with gefitinib group (26.7%, P<0.001). The disease control rate of BM was 71.1% in gefitinib-WBRT group and 42.2% in gefitinib group (P=0.006). The median time to progression of BM was 10.6 months in gefitinib-WBRT group and 6.57 months in gefitinib group (P<0.001). The median overall survival(OS) of gefitinib-WBRT and gefitinib alone group was 23.40 months and 14.83 months, respectively (HR, 0.432, P=0.002). Conclusion: Gefitinib plus concomitant WBRT had higher response rate of BM and significant improvement in OS compared with gefitinib alone in treatment of BM from NSCLC.
Keywords
Non-small-cell lung cancer; gefitinib; whole brain radiotherapy; brain metastasis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bianco C, Tortora G, Bianco R, et al (2002). Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res, 8, 3250-8.
2 Bonner JA, Harari PM, Giralt J, et al (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 354, 567-78.   DOI   ScienceOn
3 Ceresoli GL, Cappuzzo F, Gregorc V, et al (2004). Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol, 15, 1042-7.   DOI   ScienceOn
4 Das AK, Sato M, Story MD, et al (2006). Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res, 66, 9601-8.   DOI
5 Das AK, Chen BP, Story MD, et al (2007). Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res, 67, 5267-74.   DOI
6 Fidler IJ, Yano S, Zhang RD, et al (2002). The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol, 3, 53-7.   DOI
7 Furuse K, Kamimori T, Kawahara M, et al (1997). A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in nonsmall- cell lung cancer with brain metastasis. Br J Cancer, 75, 614-8.   DOI
8 Gow CH, Chien CR, Chang YL, et al (2008). Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res, 14, 162-8.   DOI
9 Heimberger AB, Learn CA, Archer GE, et al (2002). Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFRtyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res, 8, 3496-502.
10 Hotta K, Kiura K, Ueoka H, et al (2004). Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer, 46, 255-61.   DOI
11 Huang SM, Li J, Armstrong EA, et al (2002). Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res, 62, 4300-6.
12 Jackman DM, Holmes AJ, Lindeman N, et al (2006). Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol, 24, 4517-20.   DOI   ScienceOn
13 Kim JE, Lee DH, Choi Y, et al (2009). Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer, 65, 351-4.   DOI
14 Ma S, Xu Y, Deng Q, et al (2009). Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer, 65, 198-203.   DOI   ScienceOn
15 Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57.   DOI
16 Moscetti L, Nelli F, Felici A, et al (2007). Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology. Cancer, 109, 274-81.   DOI
17 Park SY, Kim YM, Pyo H (2010). Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated. Mol Cancer, 9, 222.   DOI
18 Namba Y, Kijima T, Yokota S, et al (2004). Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer, 6, 123-8.   DOI
19 Nussbaum ES, Djalilian HR, Cho KH, et al (1996). Brain metastases. Histology, multiplicity, surgery, and survival. Cancer, 78, 1781-8.   DOI
20 Olak J (1999). Surgical strategies for metastatic lung cancer. Surg Oncol Clin N Am, 8, 245-57.
21 Quantin X, Khial F, Reme-Saumon M, et al (1999). Concomitant brain radiotherapy and vinorelbine-ifosfamide-cisplatin chemotherapy in brain metastases of non-small cell lung cancer. Lung Cancer, 26, 35-9.   DOI
22 Shimato S, Mitsudomi T, Kosaka T, et al (2006). EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro Oncol, 8, 137-44.   DOI
23 Shukuya T, Takahashi T, Naito T, et al (2011). Continuous EGFRTKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer, 74, 457-61.   DOI   ScienceOn
24 Takahashi H, Ohrui T, Ebihara S, et al (2004). Effect of gefitinib (ZD1839) on metastatic brain tumour. Lung Cancer, 43, 371-2.   DOI
25 van VM, Kal HB, Taphoorn MJ, et al (2002). Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep, 9, 683-8.
26 Yawn BP, Wollan PC, Schroeder C, et al (2003). Temporal and gender-related trends in brain metastases from lung and breast cancer. Minn Med, 86, 32-7.